Roller Coaster Day for Myriad Genetics from ipfinance.blogspot.com It was a bit of a roller coaster day for US biotech
Myriad Genetics as it share price plunged 9% on news that the
US Supreme Court would be reviewing it '782 patent directed towards ...
Share via E–mail | Twitter | Facebook
Fine Art: The Oddest Market of Them All? from ipfinance.blogspot.com It's not like the market for selling a large patent portfolio for many tens of millions of dollars. Still, the market for fine art is idiosyncratic and it is like no other market. From ...
Share via E–mail | Twitter | Facebook
Patents Encompassing a Human Organism from www.patentlyo.com Ex Parte Kamrava (PTAB 2012), APN 10/080,177 Download 10080177 Most Section 101 subject matter eligibility problems can be cured by integrating the ineligible subject matter with subject matter that is patent eligible. This ...
Share via E–mail | Twitter | Facebook
Lame Duck Patent Reform: AIA Technical Corrections from www.ipwatchdog.com On Friday, November, 30, 2012, a bill making technical changes to the AIA was introduced in the House of Representatives. The bill number is HR 6621. The proposed AIA package does NOT include a so-called ...
Share via E–mail | Twitter | Facebook
If Twinkies can Survive Nuclear War, They can Survive This from www.iposgoode.ca Hostess, the brilliant minds behind the TwinkieTM, filed for a motion to wind down business operations as the result of being unable to reach an agreement with the Bakery, Confectionery, Tobacco Workers and Grain Millers ...
Share via E–mail | Twitter | Facebook
Conference & CLE Calendar from www.patentdocs.org December 3-5, 2012 - Drug and Medical Device Litigation*** (American Conference Institute) - New York, NY December 4-5, 2012 - Paragraph IV Disputes*** (American Conference Institute) - San Francisco, CA December 11, 2012 - Preissuance Prior Art Submissions at the ...
Share via E–mail | Twitter | Facebook
Court Report from www.patentdocs.org By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Takeda Pharmaceutical Co. et al. v. Lupin Ltd. et al. 3:12-cv-07333; filed November 29, 2012 ...
Share via E–mail | Twitter | Facebook
News from Abroad: UK IPO Stem Cell Decisions Raise Questions Concerning the Brüstle Decision from www.patentdocs.org By Jenny Donald -- Two UK applications were rejected by a UK examiner on the ground that they constituted the 'use of human embryos for industrial or commercial purposes', which is excluded from patentability. The applications ...
Share via E–mail | Twitter | Facebook